SIGA Technologies (SIGA) reported approximately $6 million in total revenue for Q1 2026, driven by product deliveries to the Strategic National Stockpile and R&D revenues. The company faced a pretax operating loss of $5 million and a net loss of $3 million, translating to a diluted loss per share of $0.05. Notably, SIGA declared a special cash dividend of $0.60 per share, reflecting its robust cash position of $146 million and no debt, while also indicating a commitment to shareholder returns amid variable revenue cycles.
The anticipated revenue boost from a $13 million order for oral TPOXX from an Asia-Pacific customer in Q2 highlights increasing international demand. Additionally, an exclusive distribution agreement with Hikma MENA FZE for the Middle East and North Africa expands SIGA’s market reach, reinforcing its strategic positioning in global biothreat preparedness. The company continues to invest in its product pipeline, including pediatric formulations and post-exposure prophylaxis initiatives.
For market professionals, SIGA’s ability to maintain a strong balance sheet while navigating revenue variability could signal resilience and growth potential in a sector increasingly focused on biological preparedness. The ongoing international partnerships and product development efforts position SIGA favorably for future opportunities.
Source: fool.com